The first studies of purposeful alloimmunization were performed in ... and after the birth of a term RhD-positive newborn. The amount of RhIG administered is determined by the number of fetal ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...

NEW HAVEN, Conn. - Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company with a market capitalization of $32.36 million, has initiated a Phase 2 clinical trial for RLYB212, a ...

When the maternal blood type is RhD-negative and the fetal blood type is RhD-positive, antibodies can develop (alloimmunization) that can lead to hemolytic disease of the fetus and newborn.

once called Rh "sensitization," this is now known as RhD alloimmunization Manufactured by four companies in the United States, RhoGAM was the first product on the market and is the one most often ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new policy for ...